Over his distinguished career, Dr. Dong held executive positions as the Chief Operating Officer of Lilly China R&D, a subsidiary of Eli Lily and Company, and with IMPACT Therapeutics, Inc., where he served as President and CEO. Dr. Dong has been employed by Roche both in China and in the US, and other Chinese and international companies serving in R&D, Sales & Marketing, Business Development, and